# Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

> **NCT00104520** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 211 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** AZLI 75 mg two times a day (BID)/three times a day (TID)
- **DRUG:** Placebo two times a day (BID)/three times a day (TID)

## Key facts

- **NCT ID:** NCT00104520
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2011-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104520, "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00104520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*